Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartis

Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydrochloride); Maxitrol (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%; and Moxeza 0.5% (moxifloxacin hydrochloride), from Novartis.

The acquired products, which will be sold, marketed, and distributed through ImprimisRx, combined with the company’s existing ophthalmic-focused product portfolio, support Harrow’s growing ophthalmic surgical and acute care market presence.

Under the terms of the agreement, after closing, Harrow and Novartis will immediately begin a transition period where Novartis will continue to sell the products and transfer the net profit to Harrow. Following the transition period, Harrow expects to have the products manufactured by third parties and commercialize the products for the US market, while Novartis will retain all rights to the products outside of the US. Under the terms of the agreement, Harrow made a one-time payment of $14 million at closing.

"We are pleased to now be the only U.S. ophthalmic pharmaceutical company to provide both branded FDA-approved products and high-quality compounded formulations," Mark L. Baum, CEO of Harrow Health, said in a company news release. "In addition, we uniquely have self-distribution capabilities, direct to institutions like hospitals, ambulatory surgery centers, and doctors’ offices, as well as to consumers through our ImprimisRx 50-state mail order pharmacy. These acquisitions, along with previously announced transactions for AMP-100, MAQ-100, and the expansion of our relationship to sell and market Dexycu, are consistent with our strategic mission to leverage the ImprimisRx commercial platform by adding high-value FDA approved products into our family of ophthalmic pharmaceutical products. We are excited about the benefits these newest products provide our more than 10,000 customers, and we expect ImprimisRx’s commercial and distribution platform to be a tremendous advantage in the lifecycle management of these clinically valuable medicines.”

For complete product information about IOPIDINE 1%, including important safety information, please visit: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019779s025lbl.pdf.

For complete product information about IOPIDINE 0.5%, including important safety information, please visit: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020258s026lbl.pdf.

For complete product information about MAXITROL eye drops, including important safety information, please visit: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050065s061lbl.pdf

For complete product information about MOXEZA, including important safety information, please visit: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022428s002lbl.pdf.